MX2024005242A - Polinucleotidos, composiciones y metodos para la edicion del genoma. - Google Patents
Polinucleotidos, composiciones y metodos para la edicion del genoma.Info
- Publication number
- MX2024005242A MX2024005242A MX2024005242A MX2024005242A MX2024005242A MX 2024005242 A MX2024005242 A MX 2024005242A MX 2024005242 A MX2024005242 A MX 2024005242A MX 2024005242 A MX2024005242 A MX 2024005242A MX 2024005242 A MX2024005242 A MX 2024005242A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- polynucleotides
- genome editing
- editing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
- C12Y305/04005—Cytidine deaminase (3.5.4.5)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163275425P | 2021-11-03 | 2021-11-03 | |
| US202263352158P | 2022-06-14 | 2022-06-14 | |
| PCT/US2022/079124 WO2023081689A2 (en) | 2021-11-03 | 2022-11-02 | Polynucleotides, compositions, and methods for genome editing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024005242A true MX2024005242A (es) | 2024-07-02 |
Family
ID=84537879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005242A MX2024005242A (es) | 2021-11-03 | 2022-11-02 | Polinucleotidos, composiciones y metodos para la edicion del genoma. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240301377A1 (https=) |
| EP (1) | EP4426822A2 (https=) |
| JP (1) | JP2024542995A (https=) |
| KR (1) | KR20240114296A (https=) |
| AU (1) | AU2022382975A1 (https=) |
| CA (1) | CA3237303A1 (https=) |
| CL (1) | CL2024001332A1 (https=) |
| CO (1) | CO2024007019A2 (https=) |
| IL (1) | IL312508A (https=) |
| MX (1) | MX2024005242A (https=) |
| TW (1) | TW202325848A (https=) |
| WO (1) | WO2023081689A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12401411B2 (en) * | 2020-05-08 | 2025-08-26 | Telefonaktiebolaget Lm Ericsson (Publ) | Versatile AAS receiver |
| WO2021228349A1 (en) | 2020-05-11 | 2021-11-18 | Telefonaktiebolaget Lm Ericsson (Publ) | Efficient prach scheduling |
| WO2025081064A2 (en) * | 2023-10-11 | 2025-04-17 | Illumina, Inc. | Thermophilic deaminase and methods for identifying modified cytosine |
| WO2025137301A1 (en) * | 2023-12-20 | 2025-06-26 | Intellia Therapeutics, Inc. | Methods for rapid engineering of cells |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| KR940703846A (ko) | 1991-12-24 | 1994-12-12 | 비. 린네 파샬 | 갭(gap)이 형성된 2′ 변성된 올리고뉴클레오티드(gapped 2′ modifed oligonucleotides) |
| US6169169B1 (en) | 1994-05-19 | 2001-01-02 | Dako A/S | PNA probes for detection of Neisseria gonorrhoeae and Chlamydia trachomatis |
| WO2006007712A1 (en) | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents |
| CA2895155C (en) | 2012-12-17 | 2021-07-06 | President And Fellows Of Harvard College | Rna-guided human genome engineering |
| EP3608308B1 (en) | 2013-03-08 | 2021-07-21 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| AU2014227653B2 (en) | 2013-03-15 | 2017-04-20 | The General Hospital Corporation | Using RNA-guided foki nucleases (RFNs) to increase specificity for RNA-guided genome editing |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| ES2895651T3 (es) | 2013-12-19 | 2022-02-22 | Novartis Ag | Lípidos y composiciones lipídicas para la administración de agentes activos |
| EP3169309B1 (en) | 2014-07-16 | 2023-05-10 | Novartis AG | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
| ES2964690T3 (es) | 2015-09-21 | 2024-04-09 | Trilink Biotechnologies Llc | Método para sintetizar ARN con caperuza 5' |
| TWI773666B (zh) | 2016-03-30 | 2022-08-11 | 美商英特利亞醫療公司 | Crispr/cas 組分之脂質奈米粒子調配物 |
| WO2018067447A1 (en) | 2016-10-03 | 2018-04-12 | Itellia Therapeutics, Inc. | Improved methods for identifying double strand break sites |
| CA3057192A1 (en) * | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| PT3688162T (pt) | 2017-09-29 | 2024-04-23 | Intellia Therapeutics Inc | Formulações |
| AR113154A1 (es) | 2017-09-29 | 2020-01-29 | Intellia Therapeutics Inc | Polinucleótidos, composiciones y métodos para edición del genoma |
| AU2018364993B2 (en) | 2017-11-10 | 2022-10-06 | University Of Massachusetts | Targeted CRISPR delivery platforms |
| EP3850088A4 (en) * | 2018-09-07 | 2023-07-19 | Beam Therapeutics, Inc. | Compositions and methods for improving base editing |
| WO2020072605A1 (en) | 2018-10-02 | 2020-04-09 | Intellia Therapeutics, Inc. | Ionizable amine lipids |
| BR112021007123A2 (pt) | 2018-10-15 | 2021-08-10 | University Of Massachusetts | edição de base de dna programável pelas proteínas de fusão nme2cas9-desaminase |
| IL314386A (en) | 2018-12-05 | 2024-09-01 | Intellia Therapeutics Inc | amine modified lipids |
| BR112021019224A2 (pt) | 2019-03-28 | 2021-11-30 | Intellia Therapeutics Inc | Polinucleotídeos, composições e métodos para expressão de polipeptídeo |
| WO2020219876A1 (en) | 2019-04-25 | 2020-10-29 | Intellia Therapeutics, Inc. | Ionizable amine lipids and lipid nanoparticles |
| AU2020293211B2 (en) * | 2019-06-11 | 2026-03-05 | Pairwise Plants Services, Inc. | Methods of producing plants with altered fruit development and plants derived therefrom |
| CN114616002A (zh) * | 2019-09-13 | 2022-06-10 | 瑞泽恩制药公司 | 使用由脂质纳米颗粒递送的crispr/cas系统在动物中进行的转录调控 |
| CR20230305A (es) * | 2020-12-11 | 2023-11-10 | Intellia Therapeutics Inc | Polinucleótidos, composiciones y métodos para la edición del genoma que implican desaminación |
-
2022
- 2022-11-02 EP EP22826533.6A patent/EP4426822A2/en active Pending
- 2022-11-02 JP JP2024525233A patent/JP2024542995A/ja active Pending
- 2022-11-02 MX MX2024005242A patent/MX2024005242A/es unknown
- 2022-11-02 TW TW111141875A patent/TW202325848A/zh unknown
- 2022-11-02 KR KR1020247018182A patent/KR20240114296A/ko active Pending
- 2022-11-02 IL IL312508A patent/IL312508A/en unknown
- 2022-11-02 CA CA3237303A patent/CA3237303A1/en active Pending
- 2022-11-02 WO PCT/US2022/079124 patent/WO2023081689A2/en not_active Ceased
- 2022-11-02 AU AU2022382975A patent/AU2022382975A1/en active Pending
-
2024
- 2024-04-30 CL CL2024001332A patent/CL2024001332A1/es unknown
- 2024-05-01 US US18/652,180 patent/US20240301377A1/en active Pending
- 2024-05-31 CO CONC2024/0007019A patent/CO2024007019A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240301377A1 (en) | 2024-09-12 |
| JP2024542995A (ja) | 2024-11-19 |
| WO2023081689A2 (en) | 2023-05-11 |
| KR20240114296A (ko) | 2024-07-23 |
| EP4426822A2 (en) | 2024-09-11 |
| TW202325848A (zh) | 2023-07-01 |
| IL312508A (en) | 2024-07-01 |
| CO2024007019A2 (es) | 2024-06-07 |
| AU2022382975A1 (en) | 2024-05-02 |
| CA3237303A1 (en) | 2023-05-11 |
| WO2023081689A3 (en) | 2023-06-08 |
| CL2024001332A1 (es) | 2024-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024005242A (es) | Polinucleotidos, composiciones y metodos para la edicion del genoma. | |
| PH12020550359A1 (en) | Polynucleotides, compositions, and methods for genome editing | |
| PH12021552299A1 (en) | Polynucleotides, compositions, and methods for polypeptide expression | |
| MX2022011562A (es) | Métodos y composiciones para edición dirigida de genoma. | |
| ECSP22059858A (es) | Método para el tratamiento del síndrome de usher y composición del mismo | |
| MX2025009289A (es) | Inserciones de adn no virales orientadas | |
| AR123323A1 (es) | Edición genómica de reparación dependiente de homología mejorada | |
| MX2018007290A (es) | Metodos y composiciones para expresion de acido ribonucleico (arn) guia basada en polimerasa ii (pol-ii). | |
| MX2021002265A (es) | Composiciones y métodos para aumentar la edición genética basada en oligonucleótidos de donador. | |
| BR112022018585A2 (pt) | Método para melhorar a transformação genética de plantas e eficiência de edição genética | |
| MX2018014993A (es) | Uso de endonucleasa cpf1 para modificaciones de genoma de planta. | |
| MX2024002927A (es) | Metodos y composiciones para modular un genoma. | |
| BR112022001230A2 (pt) | Estratégia de design de doador para edição de genoma crispr-cas9 | |
| BR112021010781A2 (pt) | Silenciamento genético por meio de edição de genoma | |
| BR112021021149A2 (pt) | Métodos e composições para a geração de alelos dominantes utilizando a edição de genomas | |
| MX2022013362A (es) | Composiciones para tratar cancer con mutaciones de kras y usos de las mismas. | |
| MX2024002647A (es) | Edición de arn a través del reclutamiento de componentes de espliceosomas. | |
| BR112019005605A2 (pt) | métodos para modificar o genoma (nuclear) de uma célula vegetal e um gene epsps endógeno ou para produzir uma célula vegetal ou para testar a eficiência de edição de genoma, bactéria, e, vetor | |
| WO2021207651A3 (en) | Chemically modified guide rnas for genome editing with cas12b | |
| WO2023279118A3 (en) | Cytidine deaminases and methods of genome editing using the same | |
| CL2024001251A1 (es) | Composiciones y métodos de expresión del factor ix para el tratamiento de la hemofilia b. | |
| WO2021231263A3 (en) | Nucleic acid amplification methods | |
| WO2022214522A3 (en) | Compositions and methods for site-specific modification | |
| WO2025111452A3 (en) | CHEMICAL MODIFICATIONS IN PEgRNA and ngRNAs | |
| MX2024010670A (es) | Nickasas cas12a. |